MA41948A - Procédés de traitement de patients présentant des mutations dans le domaine extracellulaire du récepteur de facteur de croissance épidermique (egfr) avec une combinaison de trois anticorps anti-egfr monoclonaux entièrement humains - Google Patents
Procédés de traitement de patients présentant des mutations dans le domaine extracellulaire du récepteur de facteur de croissance épidermique (egfr) avec une combinaison de trois anticorps anti-egfr monoclonaux entièrement humainsInfo
- Publication number
- MA41948A MA41948A MA041948A MA41948A MA41948A MA 41948 A MA41948 A MA 41948A MA 041948 A MA041948 A MA 041948A MA 41948 A MA41948 A MA 41948A MA 41948 A MA41948 A MA 41948A
- Authority
- MA
- Morocco
- Prior art keywords
- egfr
- mutations
- methods
- combination
- growth factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562152707P | 2015-04-24 | 2015-04-24 | |
US201562244991P | 2015-10-22 | 2015-10-22 | |
US201662308697P | 2016-03-15 | 2016-03-15 | |
US201662323475P | 2016-04-15 | 2016-04-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA41948A true MA41948A (fr) | 2018-02-28 |
Family
ID=55911098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA041948A MA41948A (fr) | 2015-04-24 | 2016-04-22 | Procédés de traitement de patients présentant des mutations dans le domaine extracellulaire du récepteur de facteur de croissance épidermique (egfr) avec une combinaison de trois anticorps anti-egfr monoclonaux entièrement humains |
Country Status (11)
Country | Link |
---|---|
US (1) | US20160311908A1 (fr) |
EP (1) | EP3286219A1 (fr) |
JP (1) | JP2018516870A (fr) |
KR (1) | KR20170138539A (fr) |
CN (1) | CN107889463A (fr) |
AU (1) | AU2016252877A1 (fr) |
CA (1) | CA2983890A1 (fr) |
HK (1) | HK1250736A1 (fr) |
IL (1) | IL255138A0 (fr) |
MA (1) | MA41948A (fr) |
WO (1) | WO2016172584A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
MA39599A (fr) | 2014-05-14 | 2016-10-05 | Merrimack Pharmaceuticals Inc | Dosage et administration d'agents thérapeutiques anti-egfr |
JP2020517247A (ja) | 2017-04-18 | 2020-06-18 | イエール ユニバーシティ | Tリンパ球ゲノム操作のためのプラットフォームおよびそのインビボハイスループットスクリーニング法 |
CN107385066B (zh) * | 2017-08-17 | 2021-03-23 | 浙江大学 | 检测egfr基因突变的引物对、试剂盒、检测方法及应用 |
US20200347140A1 (en) * | 2017-08-30 | 2020-11-05 | Symphogen A/S | Compositions and methods for treating cancer with anti-egfr antibodies |
CN111499749B (zh) * | 2020-03-13 | 2021-11-09 | 浙江大学 | 一种西妥昔单抗突变体及应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008091701A2 (fr) * | 2007-01-25 | 2008-07-31 | Dana-Farber Cancer Institute | Utilisation d'anticorps anti-egfr dans le traitement de maladie médiée par des mutants de récepteur du facteur de croissance épidermique (egfr) |
MX338151B (es) | 2007-03-01 | 2016-04-05 | Symphogen As | Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico. |
CA2798273A1 (fr) | 2010-05-04 | 2011-11-10 | Merrimack Pharmaceuticals, Inc. | Anticorps contre le recepteur du facteur de croissance epidermique (egfr) et leurs utilisations |
US8691231B2 (en) * | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
EP2554551A1 (fr) * | 2011-08-03 | 2013-02-06 | Fundacio Institut mar d'Investigacions Médiques (IMIM) | Mutations du gène du récepteur de facteur de croissance épidermique |
-
2016
- 2016-04-22 CA CA2983890A patent/CA2983890A1/fr not_active Abandoned
- 2016-04-22 MA MA041948A patent/MA41948A/fr unknown
- 2016-04-22 CN CN201680035207.XA patent/CN107889463A/zh active Pending
- 2016-04-22 KR KR1020177033528A patent/KR20170138539A/ko unknown
- 2016-04-22 WO PCT/US2016/028987 patent/WO2016172584A1/fr active Application Filing
- 2016-04-22 JP JP2017555306A patent/JP2018516870A/ja active Pending
- 2016-04-22 EP EP16720651.5A patent/EP3286219A1/fr not_active Withdrawn
- 2016-04-22 AU AU2016252877A patent/AU2016252877A1/en not_active Abandoned
- 2016-04-25 US US15/137,081 patent/US20160311908A1/en not_active Abandoned
-
2017
- 2017-10-19 IL IL255138A patent/IL255138A0/en unknown
-
2018
- 2018-08-08 HK HK18110206.9A patent/HK1250736A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA2983890A1 (fr) | 2016-10-27 |
WO2016172584A1 (fr) | 2016-10-27 |
CN107889463A (zh) | 2018-04-06 |
JP2018516870A (ja) | 2018-06-28 |
WO2016172584A9 (fr) | 2017-03-09 |
HK1250736A1 (zh) | 2019-01-11 |
IL255138A0 (en) | 2017-12-31 |
US20160311908A1 (en) | 2016-10-27 |
EP3286219A1 (fr) | 2018-02-28 |
AU2016252877A1 (en) | 2017-11-09 |
KR20170138539A (ko) | 2017-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA41948A (fr) | Procédés de traitement de patients présentant des mutations dans le domaine extracellulaire du récepteur de facteur de croissance épidermique (egfr) avec une combinaison de trois anticorps anti-egfr monoclonaux entièrement humains | |
MA44146A (fr) | Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer | |
HK1252248A1 (zh) | 對治療劑和疾病特異性抗原進行測序、確定、配對和驗證的方法 | |
IL263783A (en) | Quinazoline and indole compounds for the treatment of medical disorders | |
MA47208A (fr) | Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 | |
HK1248719A1 (zh) | 對her2和血腦屏障受體特異性的三特異性抗體及使用方法 | |
SG11201704572UA (en) | Bispecific antibodies against cd3epsilon and bcma for use in treatment of diseases | |
CL2016002359A1 (es) | Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco | |
IL252943A0 (en) | Sunitinib formulations and methods of using them for the treatment of eye diseases | |
EA201790932A1 (ru) | Дозировка и введение нефукозилированных анти-cd40 антител | |
EA201790545A1 (ru) | Антитела и иммуноконъюгаты против her2 | |
MA52789A (fr) | Méthodes de traitement du cancer avec des anticorps anti-pd-1 | |
MA52962A (fr) | Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1 | |
DK3668513T3 (da) | Pyruvatkinase-aktiveringsmidler til anvendelse til behandling af blodsygdomme | |
EA201500314A1 (ru) | Лекарственные формы энзалутамида | |
SG11201703428SA (en) | Bispecific antibodies and methods of use in ophthalmology | |
MX2017007491A (es) | Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso. | |
GEP20217317B (en) | Combination therapy for the treatment of cancer | |
GB201504432D0 (en) | Materials and methods for diagnosis and treatment of alzheimers disease | |
EA201492282A1 (ru) | Антагонистические антигенсвязывающие белки к двум рецепторам и их применение | |
EA201691887A1 (ru) | Лечение внутрипеченочных холестатических заболеваний | |
MX2017005975A (es) | Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso. | |
ZA201804950B (en) | Indolinones compounds and their use in the treatment of fibrotic diseases | |
DK3302519T3 (da) | Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom | |
PH12015502469A1 (en) | Fcrn-binding abolished anti-igf-ir antibodies and their use in the treatment of vascular eye diseases |